Short Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Increases By 18.8%

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 13,900 shares, an increase of 18.8% from the November 15th total of 11,700 shares. Based on an average daily volume of 48,600 shares, the short-interest ratio is presently 0.3 days. Currently, 0.0% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Barinthus Biotherapeutics in a research note on Tuesday, November 19th.

Barinthus Biotherapeutics Stock Performance

NASDAQ BRNS traded up $0.09 on Friday, reaching $0.91. 20,486 shares of the stock traded hands, compared to its average volume of 80,126. Barinthus Biotherapeutics has a 12 month low of $0.80 and a 12 month high of $4.16. The company has a market cap of $36.71 million, a price-to-earnings ratio of -0.61 and a beta of -0.73. The company has a fifty day moving average price of $1.17 and a 200-day moving average price of $1.34.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.23. The firm had revenue of $14.97 million during the quarter. During the same period in the prior year, the firm earned ($0.37) EPS. As a group, research analysts anticipate that Barinthus Biotherapeutics will post -1.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Barinthus Biotherapeutics

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. Alphabet Inc. purchased a new position in Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,513,644 shares of the company’s stock, valued at approximately $2,119,000. Barinthus Biotherapeutics makes up approximately 0.1% of Alphabet Inc.’s portfolio, making the stock its 29th largest holding. Alphabet Inc. owned 3.88% of Barinthus Biotherapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.